A Role for Aldehyde Dehydrogenase (ALDH) 2 in Angiotensin II-mediated Decrease in Angiogenesis of Coronary Endothelial Cells

Overview

Journal Microvasc Res

Specialty Cardiology & Vascular Diseases

Date 2021 Jan 11

PMID 33428883

Citations 4

Authors

Bipradas Roy

Suresh Selvaraj Palaniyandi

Affiliations

Soon will be listed here.

Abstract

Diabetes-induced coronary endothelial cell (CEC) dysfunction contributes to diabetic heart diseases. Angiotensin II (Ang II), a vasoactive hormone, is upregulated in diabetes, and is reported to increase oxidative stress in CECs. 4-hydroxy-2-nonenal (4HNE), a key lipid peroxidation product, causes cellular dysfunction by forming adducts with proteins. By detoxifying 4HNE, aldehyde dehydrogenase (ALDH) 2 reduces 4HNE mediated proteotoxicity and confers cytoprotection. Thus, we hypothesize that ALDH2 improves Ang II-mediated defective CEC angiogenesis by decreasing 4HNE-mediated cytotoxicity. To test our hypothesis, we treated the cultured mouse CECs (MCECs) with Ang II (0.1, 1 and 10 μM) for 2, 4 and 6 h. Next, we treated MCECs with Alda-1 (10 μM), an ALDH2 activator or disulfiram (2.5 μM)/ALDH2 siRNA (1.25 nM), the ALDH2 inhibitors, or blockers of angiotensin II type-1 and 2 receptors i.e. Losartan and PD0123319 respectively before challenging MCECs with 10 μM Ang II. We found that 10 μM Ang II decreased tube formation in MCECs with in vitro angiogenesis assay (P < .0005 vs control). 10 μM Ang II downregulated the levels of vascular endothelial growth factor receptor 1 (VEGFR1) (p < .005 for mRNA and P < .05 for protein) and VEGFR2 (p < .05 for mRNA and P < .005 for protein) as well as upregulated the levels of angiotensin II type-2 receptor (AT2R) (p < .05 for mRNA and P < .005 for protein) and 4HNE-adducts (P < .05 for protein) in cultured MCECs, compared to controls. ALDH2 inhibition with disulfiram/ALDH2 siRNA exacerbated 10 μM Ang II-induced decrease in coronary angiogenesis (P < .005) by decreasing the levels of VEGFR1 (P < .005 for mRNA and P < .05 for protein) and VEGFR2 (P < .05 for both mRNA and protein) and increasing the levels of AT2R (P < .05 for both mRNA and protein) and 4HNE-adducts (P < .05 for protein) relative to Ang II alone. AT2R inhibition per se improved angiogenesis in MCECs. Additionally, enhancing ALDH2 activity with Alda 1 rescued Ang II-induced decrease in angiogenesis by increasing the levels of VEGFR1, VEGFR2 and decreasing the levels of AT2R. In summary, ALDH2 can be an important target in reducing 4HNE-induced proteotoxicity and improving angiogenesis in MCECs. Finally, we conclude ALDH2 activation can be a therapeutic strategy to improve coronary angiogenesis to ameliorate cardiometabolic diseases.

Citing Articles

Exposure to the Dioxin-like Pollutant PCB 126 Afflicts Coronary Endothelial Cells via Increasing 4-Hydroxy-2 Nonenal: A Role for Aldehyde Dehydrogenase 2.

Roy B, Yang Z, Pan G, Roth K, Agarwal M, Sharma R Toxics. 2022; 10(6).

PMID: 35736936 PMC: 9230950. DOI: 10.3390/toxics10060328.

Activation of aldehyde dehydrogenase 2 protects ethanol-induced osteonecrosis of the femoral head in rat model.

Lin X, Zhu D, Wang K, Luo P, Rui G, Gao Y Cell Prolif. 2022; 55(6):e13252.

PMID: 35567426 PMC: 9201375. DOI: 10.1111/cpr.13252.

Association of ALDH2 rs671 and MTHFR rs1801133 polymorphisms with hypertension among Hakka people in Southern China.

Wu H, Huang Q, Yu Z, Zhong Z BMC Cardiovasc Disord. 2022; 22(1):128.

PMID: 35346052 PMC: 8962465. DOI: 10.1186/s12872-022-02577-x.

Aldehyde Dehydrogenase 2 as a Therapeutic Target in Oxidative Stress-Related Diseases: Post-Translational Modifications Deserve More Attention.

Gao J, Hao Y, Piao X, Gu X Int J Mol Sci. 2022; 23(5).

PMID: 35269824 PMC: 8910853. DOI: 10.3390/ijms23052682.

References

Kivela R, Hemanthakumar K, Vaparanta K, Robciuc M, Izumiya Y, Kidoya H . Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling. Circulation. 2019; 139(22):2570-2584. PMC: 6553980. DOI: 10.1161/CIRCULATIONAHA.118.036099. View

Minas J, Thorwald M, Conte D, Vazquez-Medina J, Nishiyama A, Ortiz R . Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. Clin Exp Pharmacol Physiol. 2015; 42(11):1178-88. PMC: 4596772. DOI: 10.1111/1440-1681.12473. View

Roy B, Palaniyandi S . Aldehyde dehydrogenase 2 inhibition potentiates 4-hydroxy-2-nonenal induced decrease in angiogenesis of coronary endothelial cells. Cell Biochem Funct. 2020; 38(3):290-299. DOI: 10.1002/cbf.3468. View

Ohki K, Wakui H, Kishio N, Azushima K, Uneda K, Haku S . Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue. Sci Rep. 2018; 8(1):2846. PMC: 5809432. DOI: 10.1038/s41598-018-21270-8. View

Zhang H, Forman H . Signaling by 4-hydroxy-2-nonenal: Exposure protocols, target selectivity and degradation. Arch Biochem Biophys. 2016; 617:145-154. PMC: 5318232. DOI: 10.1016/j.abb.2016.11.003. View

Lee S, Fujioka S, Takahashi R, Oe T . Angiotensin II-Induced Oxidative Stress in Human Endothelial Cells: Modification of Cellular Molecules through Lipid Peroxidation. Chem Res Toxicol. 2019; 32(7):1412-1422. DOI: 10.1021/acs.chemrestox.9b00110. View

Stoll M, Steckelings U, Paul M, Bottari S, Metzger R, Unger T . The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995; 95(2):651-7. PMC: 295531. DOI: 10.1172/JCI117710. View

Pei N, Mao Y, Wan P, Chen X, Li A, Chen H . Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer. J Exp Clin Cancer Res. 2017; 36(1):77. PMC: 5466725. DOI: 10.1186/s13046-017-0542-0. View

Nakashima H, Suzuki H, Ohtsu H, Chao J, Utsunomiya H, Frank G . Angiotensin II regulates vascular and endothelial dysfunction: recent topics of Angiotensin II type-1 receptor signaling in the vasculature. Curr Vasc Pharmacol. 2006; 4(1):67-78. DOI: 10.2174/157016106775203126. View

10.

Mihalas B, Bromfield E, Sutherland J, De Iuliis G, McLaughlin E, Aitken R . Oxidative damage in naturally aged mouse oocytes is exacerbated by dysregulation of proteasomal activity. J Biol Chem. 2018; 293(49):18944-18964. PMC: 6295717. DOI: 10.1074/jbc.RA118.005751. View

11.

Lavrentyev E, Estes A, Malik K . Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res. 2007; 101(5):455-64. DOI: 10.1161/CIRCRESAHA.107.151852. View

12.

Chen C, Sun L, Mochly-Rosen D . Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc Res. 2010; 88(1):51-7. PMC: 2936126. DOI: 10.1093/cvr/cvq192. View

13.

Singh V, Le B, Khode R, Baker K, Kumar R . Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008; 57(12):3297-306. PMC: 2584136. DOI: 10.2337/db08-0805. View

14.

Clere N, Corre I, Faure S, Guihot A, Vessieres E, Chalopin M . Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer. 2010; 127(10):2279-91. DOI: 10.1002/ijc.25234. View

15.

Potente M, Gerhardt H, Carmeliet P . Basic and therapeutic aspects of angiogenesis. Cell. 2011; 146(6):873-87. DOI: 10.1016/j.cell.2011.08.039. View

16.

Dang H, Song B, Dong R, Zhang H . Atorvastatin reverses the dysfunction of human umbilical vein endothelial cells induced by angiotensin II. Exp Ther Med. 2018; 16(6):5286-5297. PMC: 6257519. DOI: 10.3892/etm.2018.6846. View

17.

Hou J, Kang Y . Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets. Pharmacol Ther. 2012; 135(3):337-54. PMC: 3458709. DOI: 10.1016/j.pharmthera.2012.06.006. View

18.

Mihalas B, De Iuliis G, Redgrove K, McLaughlin E, Nixon B . The lipid peroxidation product 4-hydroxynonenal contributes to oxidative stress-mediated deterioration of the ageing oocyte. Sci Rep. 2017; 7(1):6247. PMC: 5524799. DOI: 10.1038/s41598-017-06372-z. View

19.

Bir S, Xiong Y, Kevil C, Luo J . Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases. Cardiovasc Res. 2012; 95(1):7-18. PMC: 3378310. DOI: 10.1093/cvr/cvs143. View

20.

Ganta V, Choi M, Kutateladze A, Annex B . VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease. Circ Res. 2016; 120(2):282-295. PMC: 5453503. DOI: 10.1161/CIRCRESAHA.116.309516. View